Drug research

Obexelimab

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Obexelimab in Patients With Systemic Lupus ErythematosusNCT06559163	Zenas BioPharma (USA), LLC	Phase 2	Active not recruiting	2026-09Estimated
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)NCT06564311	Zenas BioPharma (USA), LLC	Phase 2	Active not recruiting	2025-08-28Actual
A Phase 3 Study of Obexelimab in Patients With IgG4-Related DiseaseNCT05662241	Zenas BioPharma (USA), LLC	Phase 3	Active not recruiting	2025-11-13Actual
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)NCT05786573	Zenas BioPharma (USA), LLC	Phase 3	Active not recruiting	2026-06-30Estimated

Zenas BioPharma (USA), LLCActive not recruitingPrimary completion: 2026-09 · Estimated

Trial details

Zenas BioPharma (USA), LLCActive not recruitingPrimary completion: 2025-08-28 · Actual

Trial details

Zenas BioPharma (USA), LLCActive not recruitingPrimary completion: 2025-11-13 · Actual

Trial details

Zenas BioPharma (USA), LLCActive not recruitingPrimary completion: 2026-06-30 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.